

Mechanical Support Devices in High-Risk and/or Complex PCI



David Geffen
School of Medicine



Health


Michael S. Lee, MD FACC, FSCAI
Associate Professor

Percutaneous LV Assist Devices


IABP




IMPELLA



ECMO



PCI with IABP




Advantages



- Easy
- Inexpensive (\$800)
- 7F and 8F

Disadvantages

- Increases cardiac output by 0.5 L/m





ULMCA PCI With IABP



68 y.o. male with chest pain, ST-elevation in V1-V6, shock on inotropes


ULMCA PCI With IABP



68 y.o. male with chest pain, ST-elevation in V1-V6, shock on inotropes

Balloon-pump assisted Coronary Intervention Study: *BCIS-1*


Kaplan Meier 6 month mortality




Perera D et al. JAMA 2010;304:867.

IABP-Shock II Trial

Primary Study Endpoint: 30-day Mortality



PCI with Impella





Advantages

- Augment cardiac output by 3.5 L/min
- Use up to 7 days
- Does not require stable cardiac rhythm or native cardiac output/blood pressure signal for optimal function
- Unloads left ventricle

Disadvantages



- Requires 14 F catheter
- Non-pulsatile flow
- \$20,000

ULMCA PCI With Impella




85 y.o. male with CKD, polio presents with NSTEMI


ULMCA PCI With Impella



ULMCA PCI With Impella





Rotational atherectomy



Crush technique

ULMCA PCI With Impella




Final angiography

PROTECT II Trial Design

Hemodynamic support during high-risk, non-emergent PCI, N=654
Unprotected LM or last patent conduit & $EF \leq 35\%$ or 3VD & $EF \leq 30\%$

Assess myocardium at jeopardy and indicate all stenosis considered for stenting



Primary Endpoint = MAE at 30-days


3 Month Follow-up; MAE at 90-days




PROTECT II MAE Outcome

Intent to Treat (N=447)

IABP
IMPELLA



Per Protocol (N=426)



MAE= Major Adverse Event Rate

Per Protocol= Patients that met all incl./ excl. criteria.

PCI with ECMO





Advantages

- Augment cardiac output by >4.5 L/min
- Use up to several weeks
- Does not require stable cardiac rhythm or native cardiac output/blood pressure signal for optimal function
- Does not require fluoroscopy

Disadvantages


- Requires 21F and 18F catheters
- Non-pulsatile flow
- Increases afterload
- \$25,000

ULMCA PCI With ECMO




49 y.o. male with inferior ST-elevation and cardiac arrest in ED

ULMCA PCI With ECMO




**LM stent across LCX
ECMO inserted**



Compromise of LCX

ULMCA PCI With ECMO





Final angiography



Ventricular fibrillation



ULMCA PCI With ECMO



48 y.o. male with DM who presents with MI, cardiac arrest, cardiogenic shock, on ECMO


Orbital Atherectomy

Differential Sanding and Centrifugal Force




Unique MOA treats 360° of the vessel. The diamond coated crown sands away calcium and allows healthy elastic tissue to flex away minimizing injury to the vessel.

ULMCA PCI With ECMO



2.75 x 38 mm EES




Grade 3 perforation

ULMCA PCI With ECMO




LM stenting in LAO cranial



Final angiography after
covered stent

LV Support during High-Risk PCI: LVEF + Lesion Complexity





John Wooden



“Failing to prepare is preparing to fail.”